Linked Life Data

21292687

Source:http://linkedlifedata.com/resource/pubmed/id/21292687

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21292687rdf:typepubmed:Citationlld:pubmed
pubmed-article:21292687lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C1518923lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C0677865lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C1122962lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:21292687lifeskim:mentionsumls-concept:C1518321lld:lifeskim
pubmed-article:21292687pubmed:issue3lld:pubmed
pubmed-article:21292687pubmed:dateCreated2011-2-22lld:pubmed
pubmed-article:21292687pubmed:abstractTextThis phase II study was designed to assess the safety and efficacy of gefitinib given with and following radiation therapy in children newly diagnosed with a poor prognosis brainstem glioma. Eligible patients were those with a previously untreated nondisseminated diffuse intrinsic brainstem glioma. Histological confirmation was not required, provided patients had a characteristic clinical history and MRI findings. Treatment consisted of gefitinib, administered orally, 250 mg/m(2)/day, during standard external beam radiotherapy, continuing for up to 13 monthly courses in the absence of disease progression or unacceptable toxicity. Toxicities, particularly intratumoral hemorrhage, were monitored. Pharmacokinetics and investigational imaging studies were performed in consenting patients. Forty-three eligible patients were included in the study. Therapy was well tolerated; only 4 patients were withdrawn from the study for dose-limiting toxicity after receiving therapy for 6, 9, 17, and 24 weeks. The 12- and 24-month progression-free survival rates were 20.9 ±5.6 % and 9.3 ±4%, respectively. Overall survival rates were 56.4 ±7.6% and 19.6 ±5.9%, respectively, which appear nominally superior to other contemporaneous Pediatric Brain Tumor Consortium trials. Three patients remain progression-free survivors with ?36 months follow-up. The observation that a subset of children with this generally fatal tumor experienced long-term progression-free survival, coupled with recent observations regarding the molecular features of brainstem gliomas, raises the possibility that prospective molecular characterization may allow enrichment of treatment responders and improvement in outcome results in future studies of biologically targeted agents.lld:pubmed
pubmed-article:21292687pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292687pubmed:languageenglld:pubmed
pubmed-article:21292687pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292687pubmed:citationSubsetIMlld:pubmed
pubmed-article:21292687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292687pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21292687pubmed:statusMEDLINElld:pubmed
pubmed-article:21292687pubmed:monthMarlld:pubmed
pubmed-article:21292687pubmed:issn1523-5866lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:PollackIan...lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:PoussaintTina...lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:BoyettJames...lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:KunLarry ELElld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:StewartClinto...lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:BanerjeeAnuAlld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:GeyerJ...lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:DouglasJames...lld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:KocakMehmetMlld:pubmed
pubmed-article:21292687pubmed:authorpubmed-author:BroniscerAlbe...lld:pubmed
pubmed-article:21292687pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21292687pubmed:volume13lld:pubmed
pubmed-article:21292687pubmed:ownerNLMlld:pubmed
pubmed-article:21292687pubmed:authorsCompleteYlld:pubmed
pubmed-article:21292687pubmed:pagination290-7lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:meshHeadingpubmed-meshheading:21292687...lld:pubmed
pubmed-article:21292687pubmed:year2011lld:pubmed
pubmed-article:21292687pubmed:articleTitleA phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.lld:pubmed
pubmed-article:21292687pubmed:affiliationDepartment of Neurosurgery, Children's Hospital of Pittsburgh, 4401 Penn Avenue, Pittsburgh, PA 15224, USA. pollackif@upmc.edulld:pubmed
pubmed-article:21292687pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21292687pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:21292687pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:21292687pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed